Share on StockTwits

Summer Street assumed coverage on shares of Emergent Biosolutions (NYSE:EBS) in a research note issued on Thursday, Analyst Ratings Net reports. The firm set a “buy” rating on the stock.

Shares of Emergent Biosolutions (NYSE:EBS) opened at 21.01 on Thursday. Emergent Biosolutions has a 1-year low of $13.89 and a 1-year high of $28.48. The stock’s 50-day moving average is $24.71 and its 200-day moving average is $23.95. The company has a market cap of $783.8 million and a price-to-earnings ratio of 40.90.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.55) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.14) by $0.41. The company had revenue of $53.90 million for the quarter, compared to the consensus estimate of $57.30 million. During the same quarter last year, the company posted ($0.22) earnings per share. Emergent Biosolutions’s revenue was up 25.1% compared to the same quarter last year. On average, analysts predict that Emergent Biosolutions will post $0.93 earnings per share for the current fiscal year.

Several other analysts have also recently commented on the stock. Analysts at TheStreet downgraded shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research note on Monday. Separately, analysts at Zacks upgraded shares of Emergent Biosolutions from a “neutral” rating to an “outperform” rating in a research note on Wednesday, May 7th. They now have a $28.60 price target on the stock. Finally, analysts at Zacks downgraded shares of Emergent Biosolutions from an “outperform” rating to a “neutral” rating in a research note on Monday, March 10th. They now have a $28.60 price target on the stock.

Emergent BioSolutions Inc is a biopharmaceutical company focused on protecting and enhancing life by developing and manufacturing vaccines and antibody therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.